In addition, experimental studies have shown that the use of a MCP-1 receptor blocker suppresses inflammation and reduces glomerulosclerosis, as well as that the stimulus for the nuclear synthesis of MCP-1 is associated with oxidative stress pathways, nuclear factor-kappa B transcription factor, and protein kinase C [31–34]. Here, CCL2 is linked to glomerulosclerosis.